GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
cilgavimab is an approved drug (EMA (2022))
Compound class:
Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [3]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the BA.1 omicron (B.1.1.529) SARS-CoV-2 variant. Cilgavimab as a single agent rmore effectively neutralises the BA.2 omicron subvariant than tixagevimab in vitro [2], so the combination retains neutralising activity.
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. EU EMA (2022) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11777 | cilgavimab |
| Synonyms |
| AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab) |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1106 |
| Other databases | |
| GtoPdb PubChem SID | 434321764 |
| Search PubMed clinical trials | cilgavimab |
| Search PubMed titles | cilgavimab |
| Search PubMed titles/abstracts | cilgavimab |
